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Abstract
The purpose of this commentary is to describe the unintended effects ethics committees may have
on research and to analyse the regulatory and administrative problems of clinical trials.
Discussion: The Finnish law makes an arbitrary distinction between medical research and other
health research, and the European Union's directive for good clinical trials further differentiates
drug trials. The starting point of current rules is that clinical trials are lesser in the interest of
patients and society than routine health care. However, commercial interests are not considered
unethical. The contrasting procedures in research and normal health care may tempt physicians to
continue introducing innovations into practice by relying on unsystematic and uncontrolled
observations. Tedious and bureaucratic rules may lead to the disappearance of trials initiated by
researchers. Trying to accommodate the special legislative requirements for new drug trials into
more complex interventions may result in poor designs with unreliable results and increased costs.
Meanwhile, current legal requirements may undermine the morale of ethics committee members.
Conclusion: The aims and the quality of the work of ethics committees should be evaluated, and
a reformulation of the EU directive on good clinical trials is needed. Ethical judgement should
consider the specific circumstance of each trial, and ethics committees should not foster poor
research for legal reasons.
Introduction
Various ethical rules and, lately, an increasing amount of
legislation have been introduced to protect research par-
ticipants. Ethical codes target the researchers, but ethical
committees have come into existence to aid the researcher
and to ensure that rules are followed. Ethical rules and
codes have emerged within medical research, and still
today in most countries, the legal requirements for
research protocols to be checked by ethics committees are
confined to medical research.
Clinical trials are used variously to obtain unbiased esti-
mates of the value of health technologies, for administra-
tive purposes (e.g. for registering medicines), to get
opinion leaders to commit, and for marketing. Currently,
most clinical trials concern new drugs or new indications
for drugs. Dorman et al.'s [1] analysis of trials in acute
stroke from 1955–95 showed that only 12% tested non-
drug interventions. Active and successful research in bio-
medicine along with powerful financing – most com-
Published: 04 October 2005
Health Research Policy and Systems 2005, 3:6 doi:10.1186/1478-4505-3-6
Received: 31 January 2005
Accepted: 04 October 2005
This article is available from: http://www.health-policy-systems.com/content/3/1/6
© 2005 Hemminki; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
Health Research Policy and Systems 2005, 3:6 http://www.health-policy-systems.com/content/3/1/6monly by the drug firms – have made drug trials a central
element of clinical research.
The main aim of ethics committees is to protect patients
involved in research. However, it has been asked whether
the committees do more harm than good, with research-
ers expressing concern at the negative impact on research
[see for e.g. [2,3]]. Experts have identified serious prob-
lems in the processes [4,5,3], while a great variability in
the criteria used by the committees is reported both
within and between countries [6-10,3], with most of the
empirical studies looking at ethics committees come from
the U.K. The problems listed include too much work for
voluntary committee members, slowness (crucial for stud-
ies with time-limited budgets), varying criteria used by
different committees, a lack of training of the members of
ethics committees, repeat handling of multicenter trials,
and excessive costs. Less criticism has been made of omis-
sions – what is allowed to happen that should not be [11],
or the waste of limited clinical research capacity on trivial
research [12].
The purpose of this article is to describe the unintended
effects ethics committees may have on research, using Fin-
land as an example and focusing on clinical trials. I will
analyse some of the regulatory and administrative prob-
lems associated with clinical trials and suggest solutions.
Finland is a Northern European welfare state with a pop-
ulation of about 5 million people. Trials of new drugs are
common in Finland (tenfold higher than might be
expected on the basis of the size of the Finnish popula-
tion) [13], with 287 new drug trials reported to the drug
regulatory authority in 2001 [14].
This article is based on observations drawn from reports
of clinical trials, both published and unpublished; author-
itative advice for conducting trials; my own experience of
submitting research to ethics committees, judging
research protocols in funding organizations and sitting in
Finnish ethics committees. Much of my experience is
based on material that is, or has been, confidential, and so
I will amalgamate the information for purposes of ano-
nymity.
Discussion
The regulation of clinical trials and ethics committees
In Finland, ethics committees were first established volun-
tarily in the 1970s, whilst later their tasks and composi-
tion were regulated through a 1999 Act on medical
research [15,13]. Only medical research ("research, which
affects human integrity and is led by physicians") is
expected to be submitted to ethics committees for prior
evaluation. The European Union good clinical trials direc-
tive [16] was integrated into the Finnish national law in
spring 2004, differentiating drug trials as a subgroup that
is subject to more detailed regulation. In addition, the
directive added many administrative and surveillance
tasks in regard to drug trials, some of which are only
vaguely related to ethics, such as insurance, compensation
of injuries, and external surveillance of adverse drug
events.
The Finnish law requires that informed consent is obliga-
tory in all drug trials, and the procedures are regulated in
detail; in non-drug clinical trials, informed consent may
be waived in exceptional circumstances. Informed con-
sent is defined such that the people who are "the targets"
of the trial will be included in the study only after the trial
has been described to them honestly and in detail, and
they have then voluntarily given their permission, free of
any pressures. The consent "must be written, dated and
signed", and in the case of incapable persons, this should
be made by his or her legal representative. If the person
cannot write, oral consent may be accepted in the pres-
ence of at least one witness [16]. The Finnish Act (Sublaw
986/1999) gives a detailed list of the formal requirements
of informed consent and additional details on how to ask
for informed consent and which kinds of documents are
needed are given by drug control authorities and the cen-
tral ethics committee. One requirement is that a copy of
the signed consent is to be given to the patient or other
research participant, suggesting a contract arrangement.
Informed consent on data acquisition and its use is much
vaguer. In general, the legal and ethical issues of data use
in health research are a muddle due to law changes over
time, historic data sets, commercial interest, and special
questions of genetic data or other biological samples. In
multinational studies, the issue is complicated by the
effects of varying data protection laws and their interpre-
tation in different countries. Many researchers have
decided to avoid the problems by asking for informed
consent from the patient to also use his/her data outside
the current research frame. This consent is likely to be
uninformed, because an average patient does not know,
for example, what information can be obtained from a
blood sample or what data national registers contain, or
what does anonymity of genetic samples imply. In clinical
trials, informed consent for data storage or transfer often
ends up being a quasi-action from an ethical point of
view.
Current ethical rules in Finland do not classify commer-
cial interests as unethical, and they do not need to be
revealed to trial participants. Patients may be asked to join
trials with designs favouring the studied therapy or they
are asked to join trials intended to accustom physicians to
prescribing a certain therapy through their trial participa-
tion. A large number of trials remain unpublished (withinPage 2 of 5
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favouring the therapy being studied are more likely to be
published [17-22]. A common motive for patients to take
part in research is an altruistic wish to help medicine
develop for the common good, and were the patients to
know that the trial was created for commercial reasons
and/or the results would remain unavailable, they may
not have participated.
Double standards on informed consent
Current rules for Finnish ethics committees – for example,
as expressed in the EU directive on good clinical trials –
start from the idea that clinical trials are, by definition,
lesser in the interests of the patient and society than rou-
tine health care. The ethical codes do not explain why an
intervention that is already used in patient care automati-
cally requires an informed consent within a research set-
ting [23-25]. In ordinary health care, the same
intervention may be prescribed by less experienced and
knowledgeable practitioners. In the words of the paedia-
trician Richard Smithells: "I need permission to give a
drug to half of my patients, but not to give it to them all"
[cited by [23]].
Even though the idea of a physician being a consultant to
help the patient make an informed choice has been put
forward, it is likely that this consumerism in health care
will only expand into issues where lay-persons have the
main responsibility for health decisions, such as in the
field of prevention and some chronic diseases. In medical
research, current ethics have adopted the consumer
model, largely putting the responsibility on the patient
regardless of the nature of the issue being studied.
The contrast between the procedures required in research
and normal health care is striking. Additional research
requirements may tempt physicians to continue the old
method of introducing innovations into practice by rely-
ing on unsystematic and uncontrolled observations. In
the case of new drugs, the inflexible requirement of
informed consent in emergency situations with critically
ill patients may be unethical and/or unfeasible. It may
result in the future with emergency medication being
based on uncontrolled experimentation.
In practice, asking for informed consent is often some-
thing of a performance, in which patients and physicians
are acting as if a truly informed consent was asked for. In
many situations, patients cannot or prefer not to make an
informed choice [26]. Moreover, even if such an attempt
at truly informed consent is made, it is not often success-
ful. Diseases and ill health are concentrated among the
aged. Most patient information leaflets and consent forms
are long with difficult language [27,28].
Impact on ethics committees
In many countries, ethics committees have been trans-
formed from bodies providing advice into administrative
bodies observing that rules are followed [for the U.K., see
[29]]. If in conflict, the law precedes ethics. The legal
requirements used in judging the ethicality of clinical tri-
als may undermine the morale of the members of ethics
committees. Giving positive statements on research proto-
cols fulfilling legal requirements, yet wasting resources
and bringing no value to health may create cynicism and
decrease true interest in their work. Such situations
include accepting marketing research disguised as scien-
tific research, or accepting patient information leaflets
which contain all the necessary information, but which
are unlikely to be understood by the target group. Giving
a negative statement on important ethical research that
does not fulfil legal requirements may also undermine
morale.
Impact on research orientation
Tedious and bureaucratic rules may result in more and
more incentives being necessary to persuade physicians
and their employers to carry out trials, making trials more
expensive. Trials initiated by researchers may disappear
and only those trials having a rich sponsor will survive.
We are already in a situation where most drug trials are
paid for by drug companies [1,30-33]. In the U.K., non-
commercial sources have also extensively supported clini-
cal trials, including non-drug trials, but in recent years
there has been a clear decline [34].
"Ethical" codes and legislation may lead to trials becom-
ing tedious, expensive and factory-like, alienating inter-
ested minds and health service providers. In the worst
scenario, research resources are wasted, answers are
received to unimportant questions, and scientists turn to
other types of health research.
The current Finnish legislation and many international
codes have been made to accommodate the special
requirements of new drug trials and they do not fit well
into established therapies or into more complex interven-
tions, such as prevention and ways of organizing services.
Trying to accommodate the legal requirements may result
in poor designs with unreliable results and increased
costs, and interest in studying complex interventions may
diminish. For example, if the requirement of informed
consent is interpreted rigidly, cluster randomization
would become unfeasible.
Conclusion
Comparative trials that answer important health or health
service questions and which are not biased by commercial
interests are needed. They should be applicable to real lifePage 3 of 5
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questions to be studied.
The research question and field circumstances should
determine how clinical trials should be done. When the
Helsinki Declaration was formulated, Bradford Hill [35],
an innovator behind clinical trials, claimed that there is
no one way of doing clinical trials ethically, and giving
detailed advice as if there were will harm both research
and ethics. He argued that ethical judgement has to con-
sider the specific circumstances of each trial. General
advice for trial design and ethics are useful in giving inex-
perienced researchers help in their work, but as Foster [29]
has argued, to decide what is ethically appropriate
requires a thoughtful balancing between different moral
approaches and cannot simply be substituted by regula-
tion and rules.
It seems that ethics committees have sometimes become
an extra burden instead of an aid to bettering clinical tri-
als. The external review by ethics committees should be
advisory and they should not be censoring and preventing
research, but advising and helping researchers to carry out
responsible research. Ethics committees should judge the
ethical components, free from rigid detailed rules, guided
by general principles, enriched in international debate.
Ethics include the fair use of health care resources and the
potential value of the study. The burden of judging the
benefits and risks should not be put solely onto individual
patients via informed consent.
The concept and practical application of informed con-
sent should be rethought for trials with interventions
which can be used without informed consent in everyday
practice. Normal health care and research on existing
practices should have similar ethical rules [24,25]. Opting
out and "non-compliance" are the rights of a person, both
in research and normal care. But people cannot (individ-
ually) beforehand decline from being asked to enter mass
screening, or choose hospital wards randomized to vary-
ing (established) treatment policies. Their role in deciding
on emergency care is limited, too. Whether or how indi-
viduals are informed about the trial should depend on the
intervention. For screening, Irwig et al. [36] have pro-
posed a survey of the target population's interest in partic-
ipating after being fully informed before the offer of
screening. For trials comparing different treatment poli-
cies (pragmatic trials), providing information to and gain-
ing permission from the communities in which the
research is being carried out is an option. For collective
permission to be useful, it may, however, need public
education on what the trials are and why they are valua-
ble.
Participation in trials with non-commercial interests
should be seen as a professional responsibility [37], and
clinical trials with existing therapies or service provision
should be considered a part of health services.
The role of ethics committees should be expanded to
cover commercial interests. Ethics committees should
guarantee that all potential participants, both physicians
and patients, are aware of the financer, and what, if any,
are the commercial aims, as well as what compensation is
paid, and whether results will be publicly available.
The rules and legislation governing the work of ethics
committees as well as the quality of their work should be
evaluated. Observations suggest that ethics committees
are doing tasks which do not suit them, and which pre-
vent them from concentrating on the real issues. Further-
more, there is a worry that the new EU legislation may
worsen the opportunities to do trials which are in the
patients' interest. An urgent task in Europe is to reformu-
late the EU directive on good clinical trials and to discuss
ethics from a wider perspective.
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